Haisco Pharmaceutical Group Co., Ltd.
002653
Rangering i aksjer
#2009
Haisco Pharmaceutical Group Co., Ltd., along with its subsidiaries, operates... Haisco Pharmaceutical Group Co., Ltd., along with its subsidiaries, operates within China, focusing on the research, production, and distribution of a diverse range of pharmaceutical products. Their offerings span various dosage forms, including small and large volume injections, freeze-dried and conventional powder injections, and active pharmaceutical ingredients (APIs). These medications target numerous therapeutic areas such as anti-infectives, digestive system disorders, blood system conditions, nervous system ailments, parenteral nutrition, antibiotics, emergency care, anesthesiology, and oncology. Furthermore, the company provides drugs in tablet, capsule, granule, and ointment forms for cardiovascular health, infectious diseases, digestive issues, central nervous system (CNS) conditions, diabetes, and hepatic diseases. Established in 2000 and based in Shannan, China, the company adopted its current name, Haisco Pharmaceutical Group Co., Ltd., in March 2016, having previously been known as Xizang Haisco Pharmaceutical Group Co., Ltd.
Aksjekurs
$9.03
Markedsverdi
$10.30B
Endring (1 dag)
4.55%
Endring (1 år)
24.15%
Land
CN
Handel Haisco Pharmaceutical Group Co., Ltd. (002653)
Kategori
Healthcare
P/B-forhold for Haisco Pharmaceutical Group Co., Ltd. (002653)
P/B-forhold per October 2026 TTM: 12.97
Ifølge Haisco Pharmaceutical Group Co., Ltd. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 12.97. Ved slutten av 2023 hadde selskapet et P/B-forhold på 6.30.
P/B-historikk for Haisco Pharmaceutical Group Co., Ltd. fra 2008 til 2026
P/B-forhold ved hvert års slutt
| År | P/B-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 12.97 | 46.74% |
| 2024 | 8.84 | 40.24% |
| 2023 | 6.30 | -20.06% |
| 2022 | 7.88 | 2.00% |
| 2021 | 7.73 | 19.70% |
| 2020 | 6.46 | -29.69% |
| 2019 | 9.18 | 53.03% |
| 2018 | 6.00 | 4.90% |
| 2017 | 5.72 | -22.51% |
| 2016 | 7.38 | -31.60% |
| 2015 | 10.79 | 23.70% |
| 2014 | 8.72 | -21.38% |
| 2013 | 11.10 | 72.12% |
| 2012 | 6.45 | -27.45% |
| 2011 | 8.89 | -39.72% |
| 2010 | 14.74 | -68.96% |
| 2009 | 47.50 | 59.68% |
| 2008 | 29.74 | 0.00% |
P/B-forhold for lignende selskaper eller konkurrenter
| Selskap | P/B-forhold | Forskjell i P/B-forhold | Land |
|---|---|---|---|
| 6.251 | -51.81% |
US
|
|
| 13.2547 | 2.18% |
US
|
|
| 4.208 | -67.56% |
AU
|
|
| 6.1824 | -52.34% |
NL
|
|
| - | - |
CH
|
